Can I be treated with acotinib after surgery?

Acalabrutinib (Acalabrutinib) is usually used to treat specific types of leukemia and lymphoma, such as chronic lymphocytic leukemia (CLL), small cell lymphoma (SLL), follicular lymphoma (FL), and diffuse large B cell lymphoma (DLBCL). For the treatment of liver cancer, acotinib is not the first choice drug because its mechanism of action mainly targets the B cell receptor signaling pathway, rather than the typical target of liver cancer. Liver cancer is usually treated with a variety of comprehensive treatments such as surgical resection, radiotherapy, chemotherapy, targeted therapy, and immunotherapy, but acotinib is not a conventional treatment option.

However, for some patients who may be at high risk for recurrence or metastasis after surgical resection, acotinib may be considered. For example, patients are given systemic treatment after surgery to prevent recurrence or metastasis of liver cancer. However, this treatment option needs to be carried out under strict physician supervision. Doctors need to weigh the pros and cons and decide whether to use acotinib or other treatments based on the patient's specific situation and clinical guidelines.

It should be noted that acotinib may cause some adverse reactions, such as hematological abnormalities, gastrointestinal reactions, etc., and the dose may need to be adjusted or used with caution in patients with impaired liver function. Therefore, in patients using acotinib to treat liver cancer, doctors need to carefully assess the patient's liver function and overall health status and fully communicate with the patient to ensure the safety and effectiveness of the treatment.

In summary, acotinib is not usually used as the first-choice treatment for liver cancer, but in some specific cases, such as high-risk patients after surgery, systemic treatment with acotinib may be considered to prevent the recurrence or metastasis of liver cancer. However, this needs to be done under the guidance of a physician, and the patient needs to be closely monitored for treatment response and adverse events.